Citius Oncology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $68.2M
- Price
- $0.734
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.31%
- Volume
- 13.5K
About
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Quick stats
Shares outstanding93.0M
Computed float26.9M
Float / shares28.9%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001851484
AI Summary
AI-generated1/12
standardbullishearnings
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals reported fiscal third quarter revenue of $1.5 million, marking the first commercial sales from the LYMPHIR launch, with $7.1 million in revenue recorded for the nine-month period.
Commercial momentum accelerated during the quarter, with LYMPHIR now available at 44 institutions and July setting a record for institutional vial orders.
The company ended the quarter with $17 million in cash and equivalents but posted a net loss of $8.9 million, having recently bolstered liquidity with approximately $24 million in proceeds from warrant exercises and a term loan.
Red flags
- Cash position of $17.0 million versus quarterly operating loss of $8.9 million indicates limited runway without further financing.